Orchestra BioMed (OBIO) said Wednesday it presented data showing that its investigational atrioventricular interval modulation, or AVIM, therapy improved echocardiographic markers of diastolic dysfunction, a key factor in heart failure among hypertensive patients.
The company said a retrospective analysis of its Moderato II study data showed that patients with diastolic dysfunction who received six months of AVIM therapy achieved lower office and ambulatory systolic blood pressure.
Echocardiographic changes were consistent with improved myocardial relaxation and diastolic compliance, the company added.
Price: 5.35, Change: -0.03, Percent Change: -0.56
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.